Analysis updated on Oct. 9, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for STEK is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
| Metric | STEK | Rank |
|---|---|---|
| EPS | $0.00 | – |
| Metric | STEK | Rank |
|---|---|---|
| ROA | -100.0% | 8/8 |
| ROIC | 23.4% | 3/6 |
| Operating Margin | -132.8% | 7/7 |
| Net Margin | -225.8% | 7/8 |
| EBT Margin | -189.4% | 7/8 |
| Tax Rate | 0.0% | – |
| Metric | STEK | Rank |
|---|---|---|
| Current Ratio | 0.05x | 7/7 |
| Quick Ratio | 0.02x | 7/7 |
| Interest Coverage | -101.5x | 7/7 |
| Working Capital | -$11M | 5/7 |
| Metric | STEK | Rank |
|---|---|---|
| Operating Cash Flow | -$1M | 7/8 |
| Metric | STEK | Rank |
|---|---|---|
| Inventory Turnover | 1.4x | 7/7 |
| Days Inventory | 257 days | 1/7 |
| Payables Period | 4881 days | 1/6 |
| Metric | STEK | Rank |
|---|---|---|
| Operating Income | -$1M | 5/7 |
| Net Income | -$3M | 6/8 |
| R&D Expense | $0.00M | – |
| Cost of Goods Sold | $440K | 7/8 |
| Total Current Assets | $570K | |
| Cash & Short-term Investments | $250K | |
| Accounts Receivable | $0.00M | |
| Inventory | $310K | |
| Total Liabilities | $11M | |
| Short-term Debt | $5M |
Companies classified under the same SEC industry code as Stemtech Corp (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeMIRAMAR, Fla., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation ("Stemtech"), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has ...
NAPLES, FL / ACCESS Newswire / October 20, 2025 / Stemtech Corporation (STEK), the global leader and pioneer in stem cell nutrition, announces core products are available for shipment after overcoming ...
Get the latest news on STEMTECH CORP by Stemtech Corp. stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on STEMTECH CORP by Stemtech Corp. performance ...
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
A per-ticker accuracy statistic for STEK is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Stemtech Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 9, 2026.
8 issuers in our coverage, STEK included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cencora, Inc. (COR), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Hwh International Inc. (ESYN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.